Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/14/2025 | $890.00 | Buy | Rothschild & Co Redburn |
| 6/30/2025 | Buy → Hold | Argus | |
| 5/30/2025 | $662.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 5/30/2025 | $580.00 | Overweight → Equal Weight | Wells Fargo |
| 5/14/2025 | $700.00 | Neutral → Buy | Citigroup |
| 4/22/2025 | $695.00 | Overweight | Cantor Fitzgerald |
| 2/5/2025 | $762.00 → $834.00 | Market Perform → Outperform | Leerink Partners |
| 1/16/2025 | $1130.00 → $738.00 | Buy → Neutral | UBS |
Rothschild & Co Redburn initiated coverage of Regeneron Pharma with a rating of Buy and set a new price target of $890.00
Argus downgraded Regeneron Pharma from Buy to Hold
RBC Capital Mkts downgraded Regeneron Pharma from Outperform to Sector Perform and set a new price target of $662.00
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
4 - REGENERON PHARMACEUTICALS, INC. (0000872589) (Issuer)
8-K - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
SCHEDULE 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
13F-HR - REGENERON PHARMACEUTICALS, INC. (0000872589) (Filer)
For Immediate Release: May 20, 2022 Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older weighing at least 40 kilograms (which is about 88 pounds). Today’s action marks the first FDA approval of a treatment for EoE. “As researchers and clinicians have gained knowledge about eosinophilic esophagitis
TARRYTOWN, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. The European Commission is expected to make a final decision on the application in the coming months. Libtayo was approved by the U.S. Food and Drug Administration (FDA) for these patients in the U.S. earlier this month. The positive opinion is supported by results from the global Ph
USA News Group News Commentary –Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is accelerating across oncology as companies advance novel mechanisms targeting previously difficult-to-treat patient populations. The cancer immunotherapy market reached $226 billion in 2024 and continues expanding rapidly, driven by precision approaches that pair targeted agents with immunotherapy, identify genetic vulnerabilities, and deploy radioligand therapies for metastatic disease[1]. Recent clinical data demonstrating high response rates in biomarker-selected populations underscore the shift toward mole
TARRYTOWN, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society for Medical Oncology (ESMO) 2025 Meeting, taking place from October 17-21 in Berlin, Germany. Highlights include new Phase 3 C-POST data on an every 6-week dosing regimen for the PD-1 inhibitor Libtayo® (cemiplimab) as adjuvant treatment for cutaneous squamous cell carcinoma (CSCC) with a high risk of recurrence. "Our oncology presentations at ESMO represent important progress toward expanding options for people with difficult-to-treat cancers," said Israel Lowy,
TARRYTOWN, N.Y., June 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the launch of a pioneering matching program for donations to Good Days, an independent national non-profit charitable organization, to support Good Days' Retinal Vascular and Neovascular Disease Fund. Through this initiative, Regeneron has committed to matching donations up to a total of $200 million at a one-to-one rate for the remainder of the 2025 calendar year, enabling more patients to affordably access essential medicines that help protect their vision. "We are proud to support Good Days with this unprecedented philanthropic effort," said Leonard Schleifer, M.D., Ph.D.,
TARRYTOWN, N.Y., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio, Inc. to acquire full development and commercialization rights to its pipeline of investigational novel immune cell therapies, along with its discovery and clinical manufacturing capabilities. 2seventy bio employees who support the acquired programs will join Regeneron Cell Medicines, a newly formed research & development (R&D) unit to advance cell therapies and combination approaches in oncology and immunology. "Regeneron and 2seventy share a relentless commitment to push the boundaries of scie
NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email det
TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailin
TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on Tuesday, April 29, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detai
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)
SC 13G/A - REGENERON PHARMACEUTICALS, INC. (0000872589) (Subject)